Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent - Regional Cancer Care Associates LLC

Clinical Trials

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome
Locations
Bethesda
Sponsor
Onconova Therapeutics, Inc.
Protocol Number
04-30
Cancer Diagnosis
To Learn More Call
201-510-0910